REPORT OVERVIEW
-
Request a Free Sample to learn more about this report
The global recombinant human serum albumin market size was in USD 75 million 2022. As per our research, the recombinant human serum albumin market is expected to reach USD 114.1 million by 2028, exhibiting a CAGR of 7.3% during the forecast period. The COVID-19 pandemic has been unprecedented and staggering, with experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden decline in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
The recombinant human serum albumin (rHSA) stands as a biopharmaceutical achievement originating from the realm of genetic engineering, more precisely, the domain of recombinant DNA technology. Human Serum Albumin (HSA), an intrinsic protein within blood plasma, boasts its versatile attributes. At its core, it assumes the vital responsibility of upholding osmotic equilibrium, shuttling diverse molecules, and exhibiting an extensive ligand-binding spectrum.
COVID-19 Impact: Increased Demand for Biopharmaceuticals among Population to Fuel Market Growth
The COVID-19 pandemic highlighted the significance of biopharmaceuticals, encompassing vaccines and therapeutic proteins, as crucial tools for disease management and treatment. This surge in recognition led to an increased requirement for recombinant human serum albumin, a vital component frequently employed in the synthesis and structuring of such biopharmaceuticals.
Manufacturing disruptions arising from lockdowns, restrictions, and labor scarcities across different areas posed a potential threat to recombinant human serum albumin production. Furthermore, disruptions in the supply chain adversely influenced the accessibility of essential raw materials and equipment.
LATEST TRENDS
"Increased Demand for Biopharmaceuticals, and Shift Towards Personalized Medicine to Fuel Market Growth "
The surge in biopharmaceutical demand emerged as a notable force propelling the recombinant human serum albumin market. A rising prevalence of chronic ailments like cancer, diabetes, and autoimmune disorders contributed to this trend. Biopharmaceuticals, encompassing therapeutic proteins and monoclonal antibodies, demonstrated efficacy in managing these intricate conditions. These biologics, derived from living organisms, were gaining prominence within the pharmaceutical sector, notable for their specificity that aligns with precise disease mechanisms.
SEGMENTATION
-
Request a Free Sample to learn more about this report
- By Type
On the basis of type, the market is divided into OsrHSA, and ScrHSA.
- By Application
On the basis on application, the market is segmented into cell culture media, medical supplements, and others.
DRIVING FACTORS
"Biopharmaceutical Industry Growth to Fuel Market Growth "
The biopharmaceutical sector's growth stands out as a pivotal catalyst driving the recombinant human serum albumin market expansion. Continuous advancements in biotechnology, inclusive of genetic manipulation and protein expression techniques, have not only facilitated the streamlined production of intricate biopharmaceuticals but have also contributed to the recombinant human serum albumin market growth. Remarkably, the recombinant human serum albumin, synthesized through recombinant methods, seamlessly aligns with these leaps in innovation, solidifying its position as an indispensable component across diverse applications and contributing to the overall market growth.
"Rise in Chronic Diseases to Stimulate Market Progress"
The escalation of chronic illnesses serves as a significant propellant impacting the recombinant human serum albumin market. Conditions such as cancer, diabetes, cardiovascular ailments, and autoimmune disorders fall under the umbrella of chronic diseases and have observed a notable rise in prevalence. This mounting health challenge has consequently surged the request for efficacious interventions capable of both overseeing and alleviating the enduring effects of these prolonged health conditions.
RESTRAINING FACTOR
"Production Costs to Harm Market Growth "
Producing recombinant human serum albumin through recombinant methods can incur significant expenses due to the requirement for specialized machinery, stringent purification procedures, and adherence to regulatory standards. The elevated production costs have the potential to impede its accessibility and uptake, especially within environments with limited resources.
REGIONAL INSIGHTS
-
Request a Free Sample to learn more about this report
"North America Leveraging their Robust Biopharmaceutical Sectors to Drive Market Share "
North America to hold the largest recombinant human serum albumin market share. Exploring the recombinant human serum albumin market provides valuable insights into its dynamic trends and potential across diverse geographic regions. It's notable that the U.S. and Canada are positioned to secure substantial recombinant human serum albumin market share in the recombinant human serum albumin domain, leveraging their robust biopharmaceutical sectors and advanced research capacities.
The prevalence of well-funded healthcare systems, coupled with supportive regulatory frameworks, creates an environment conducive to pioneering advancements, which collectively underpins the market's expansion. Furthermore, the active participation of prominent pharmaceutical and biotechnology entities deeply vested in biopharmaceutical research and development serves as an additional driving force, amplifying the market's growth trajectory.
KEY INDUSTRY PLAYERS
"Multitude of Companies that Played a Pivotal Role in Expansion of the Market"
Numerous significant players within the industry were actively participating in the recombinant human serum albumin market. Among them, a notable biotechnology company stands out, specializing in the manufacturing of recombinant human serum albumin and a range of albumin-based products with diverse applications, spanning from drug delivery to cell culture.
List of Market Players Profiled
- Albumedix (U.K.)
- Merck (Europe)
- Ventria (U.S.)
- NCPC (Asia Pacific)
- HiMedia (Asia Pacific)
REPORT COVERAGE
The future demand for the recombinant human serum albumin market is covered in this study. The research report includes the impact of increased demand for biopharmaceuticals due to the COVID-19 impact. The report covers the latest trends in increased demand for biopharmaceuticals. The paper includes a segmentation of the recombinant human serum albumin market. The research paper includes the driving factors that are biopharmaceutical industry growth to fuel market growth. The report also covers information on regional insights where the region which has emerged leading market for recombinant human serum albumin.
| REPORT COVERAGE | DETAILS |
|---|---|
Market Size Value In |
US$ 75 Million in 2022 |
Market Size Value By |
US$ 114.1 Million by 2028 |
Growth Rate |
CAGR of 7.3% from 2022 to 2028 |
Forecast Period |
2022-2028 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the global recombinant human serum albumin market expected to touch by 2028?
The global recombinant human serum albumin market size is expected to reach USD 114.1 million by 2028.
-
What CAGR is the global recombinant human serum albumin market expected to exhibit by 2028?
The global recombinant human serum albumin market is expected to exhibit a CAGR of 7.3% by 2028.
-
Which are the driving factors of the recombinant human serum albumin market?
The driving factors of the recombinant human serum albumin market are Biopharmaceutical Industry Growth and Rise in Chronic Diseases.
-
Which are the key players or most dominating companies functioning in the recombinant human serum albumin market?
Albumedix, Merck, Ventria, NCPC, and HiMedia are the key players or most dominating companies functioning in the recombinant human serum albumin market.
